Prehliadač alebo jeho nastavenia nie sú podporované.

Praktik.ai používa moderné webové technológie kvôli bezpečnosti, rýchlosti a spoľahlivému prihlasovaniu. Tento prehliadač ich nepodporuje alebo blokuje JavaScript, preto sa aplikácia nemusí správne načítať.

Aktualizujte prosím Chrome, Edge, Firefox alebo Safari na najnovšiu verziu a stránku potom obnovte.

Ak používate Windows 7, Windows 8 alebo Windows 8.1, Chrome a Edge už nemusia ponúkať novú verziu. V takom prípade použite novšie zariadenie alebo kontaktujte podporu Praktik.ai.

Prohlížeč nebo jeho nastavení nejsou podporované.

Praktik.ai používá moderní webové technologie kvůli bezpečnosti, rychlosti a spolehlivému přihlašování. Tento prohlížeč je nepodporuje nebo blokuje JavaScript, proto se aplikace nemusí správně načíst.

Aktualizujte prosím Chrome, Edge, Firefox nebo Safari na nejnovější verzi a stránku potom obnovte.

Pokud používáte Windows 7, Windows 8 nebo Windows 8.1, Chrome a Edge už nemusí nabízet novou verzi. V takovém případě použijte novější zařízení nebo kontaktujte podporu Praktik.ai.

Your browser or its settings are not supported.

Praktik.ai uses modern web technologies for security, speed, and reliable sign-in. This browser does not support them, or JavaScript is blocked, so the app may not load correctly.

Please update Chrome, Edge, Firefox, or Safari to the latest version and then reload this page.

If you use Windows 7, Windows 8, or Windows 8.1, Chrome and Edge may no longer offer a newer version. In that case, use a newer device or contact Praktik.ai support.

62024TJ0455_EXT

JUDGMENT OF THE GENERAL COURT (Fifth Chamber)

23 September 2026 ( *1 ) ( 1 )

(Public health – Medicinal products for human use – Orphan medicinal product for human use Ocaliva – obeticholic acid – Revocation of the conditional marketing authorisation – Procedure for review – Procedure initiated without awaiting the outcome of the renewal procedure – Consultation of an ad-hoc expert group by the EMA’s Committee for Medicinal Products for Human Use – Impartiality of the experts consulted – Declaration of a conflict of interest – Procedural defect – Principle of sound administration – Article 116 of Directive 2001/83/EC, as amended by Directive 2004/27/EC – Manifest errors of assessment – Legitimate expectations – Proportionality – Article 57 of Regulation (EC) No 726/2004 as amended by Regulation (EU) 2019/5)

In Case T‑455/24,

Advanz Pharma Ltd, established in Dublin (Ireland), represented by M. Meulenbelt, B. Baum, A. Vermulst and A. Robert, lawyers,

applicant,

supported by

CBP Portugal, established in Pousos Leiria (Portugal), represented by A. Souto Moura, P. Marques Bom, M. Maló Hipólito, M. Fernandes Cerejo and J. Silveira Botelho, lawyers,

intervener,

v

European Commission, represented by R. Lindenthal, E. Mathieu and A. Spina, acting as Agents,

defendant,

supported by

European Medicines Agency (EMA), represented by G. Gavriilidou, H. Kerr, M. van Egmond and G. Ramo, acting as Agents,

intervener,

THE GENERAL COURT (Fifth Chamber),

composed of M. Sampol Pucurull, President, J. Laitenberger (Rapporteur) and W. Valasidis, Judges,

Registrar: A. Marghelis, Administrator,

having regard to the order of 26 November 2024, Advanz Pharma v Commission (T‑455/24 R, not published, EU:T:2024:863),

having regard to the written part of the procedure, in particular:

– the orders of 14 March 2025 granting CBP Portugal and the EMA leave to intervene in support of the applicant and the Commission, respectively;

– the request for the adoption of a measure of inquiry, submitted by the applicant on 3 March 2025 and amended in the context of its observations on the statement in intervention submitted by the EMA, seeking an order from the General Court for the production of two documents,

– the request for examination of a witness, submitted by the applicant on 3 July 2025,

– the measure of organisation of procedure of 12 November 2025 and the replies of the Commission, the EMA and CBP Portugal, lodged at the Court Registry on 27 and 28 November 2025, respectively,

further to the hearing on 15 January 2026,

gives the following

Judgment

1 By its action under Article 263 TFEU, the applicant, Advanz Pharma Ltd, seeks the annulment of Commission Implementing Decision C(2024) 6281 final of 30 August 2024 (‘the contested decision’) revoking, under Article 20 of Regulation (EC) No 726/2004 of the European Parliament and of the Council, the conditional marketing authorisation granted by Decision C(2016) 8685 final for ‘Ocaliva – obeticholic acid’, an orphan medicinal product for human use.

Legal framework

2 Point 28 of Article 1 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as amended by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 (OJ 2004 L 136, p. 34), defines ‘risks related to use of the medicinal product’ as ‘any risk relating to the quality, safety or efficacy of the medicinal product as regards patients’ health or public health’ and ‘any risk of undesirable effects on the environment.’

3 Point 28a of Article 1 of Directive 2001/83, as amended by Directive 2004/27, defines the concept of a ‘risk-benefit balance’ as ‘an evaluation of the positive therapeutic effects of the medicinal product in relation to the risks as defined in point 28, first indent.’

4 The first paragraph of Article 116 of Directive 2001/83, as amended by Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 (OJ 2010 L 348, p. 74), provides:

‘The competent authorities shall suspend, revoke or vary a marketing authorisation if the view is taken that the medicinal product is harmful or that it lacks therapeutic efficacy, or that the risk-benefit balance is not favourable, or that its qualitative and quantitative composition is not as declared. Therapeutic efficacy is lacking when it is concluded that therapeutic results cannot be obtained from the medicinal product.’

5 The first paragraph of Article 2 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended by Regulation (EU) 2019/5 of the European Parliament and of the Council of 11 December 2018 (OJ 2019 L 4, p. 24), provides:

‘The definitions laid down in Article 1 of Directive [2001/83] shall apply for the purposes of this Regulation. …’

6 Article 14-a of Regulation No 726/2004, as amended by Regulation No 2019/5, provides:

‘1. In duly justified cases, to meet unmet medical needs of patients, a marketing authorisation may, for medicinal products intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases, be granted prior to the submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. …

…

3. Marketing authorisations may be granted pursuant to this Article only if the risk-benefit balance of the medicinal product is favourable and the applicant is likely to be able to provide comprehensive data.

4. Marketing authorisations granted pursuant to this Article shall be subject to specific obligations. Those specific obligations and, where appropriate, the time limit for compliance shall be specified in the conditions to the marketing authorisation. Those specific obligations shall be reviewed annually by the [European Medicines] Agency.

5. As part of the specific obligations referred to in paragraph 4, the holder of a marketing authorisation granted pursuant to this Article shall be required to complete ongoing studies, or to conduct new studies, with a view to confirming that the risk-benefit balance is favourable.

…’

7 Article 20 of Regulation No 726/2004, as amended by Regulation 2019/5, states:

‘1. Where the supervisory authorities or the competent authorities of any other Member State are of the opinion that the manufacturer or importer established within the Union territory is no longer fulfilling the obligations laid down in Title IV of [Directive 2001/83], they shall forthwith inform the Committee for Medicinal Products for Human Use and the Commission, stating their reasons in detail and indicating the course of action proposed.

The same shall apply where a Member State or the Commission considers that one of the measures envisaged in Titles IX and XI of Directive [2001/83] should be applied in respect of the medicinal product concerned or where the said Committee has delivered an opinion to that effect in accordance with Article 5 of this Regulation.

2. The Commission shall request the opinion of the [European Medicines] Agency within a time limit which it shall determine in the light of the urgency of the matter, in order to examine the reasons advanced. Whenever practicable, the holder of the authorisation for placing the medicinal product for human use on the market shall be invited to provide oral or written explanations.

…’

…

10 The recitals of Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation No 726/2004 of the European Parliament and of the Council (OJ 2006 L 92, p. 6) state:

‘(1) Before a medicinal product for human use is authorised for placing on the market of one or more Member States, it generally has to undergo extensive studies to ensure that it is safe, of high quality and effective for use in the target population. …

(2) In the case of certain categories of medicinal products, however, in order to meet unmet medical needs of patients and in the interests of public health, it may be necessary to grant marketing authorisations on the basis of less complete data than is normally the case and subject to specific obligations, hereinafter “conditional marketing authorisations”. …

(3) Although the data upon which an opinion on a conditional marketing authorisation [are] based may be less complete, the risk-benefit balance, as defined in Article 1(28a) of Directive [2001/83] should be positive. Furthermore, the benefits to public health of making the medicinal product concerned immediately available on the market should outweigh the risk inherent in the fact that additional data are still required.

…

(5) In order to ensure that the right balance is struck between facilitating access to medicines for patients with unmet medical needs and preventing the authorisation of medicines with an unfavourable risk-benefit profile, it is necessary to make those marketing authorisations subject to specific obligations. The holder should be required to complete or initiate certain studies with a view to confirming that the risk-benefit balance is positive and resolving any questions relating to the quality, safety and efficacy of the product.

(6) Conditional marketing authorisations are distinct from marketing authorisations granted in exceptional circumstances in accordance with Article 14(8) of Regulation [No 726/2004]. In the case of the conditional marketing authorisation, authorisation is granted before all data are available. The authorisation is not intended, however, to remain conditional indefinitely. Rather, once the missing data are provided, it should be possible to replace it with a marketing authorisation which is not conditional, that is to say, which is not subject to specific obligations. In contrast, it will normally never be possible to assemble a full dossier in respect of a marketing authorisation granted in exceptional circumstances.

…

(8) Since the provisions of Regulation [No 726/2004] apply to conditional marketing authorisations unless otherwise provided for in this Regulation, the procedure for evaluating a conditional marketing authorisation is the normal procedure laid down in Regulation [No 726/2004].

(9) In accordance with Regulation [No 726/2004], conditional marketing authorisations will be valid for one year on a renewable basis. The deadline for submission of a renewal application should be six months prior to the expiry of the marketing authorisation, and the opinion of the [European Medicines Agency] on the application should be adopted within 90 days of its receipt. To ensure that medicinal products are not removed from the market except for reasons related to public health, the conditional marketing authorisation should, as long as a renewal application is submitted within the deadline, remain valid until the Commission reaches a decision based on the renewal assessment procedure.

…

(11) Enhanced pharmacovigilance for medicinal products granted a conditional marketing authorisation is important and is already adequately provided for in Directive [2001/83] and Regulation [No 726/2004]. However, the time schedule for submitting periodic safety update reports should be adapted to accommodate the annual renewal of conditional marketing authorisations.’

11 Article 1 of Regulation No 507/2006 provides:

‘This Regulation lays down rules on the granting of a marketing authorisation subject to specific obligations in accordance with Article 14(7) of Regulation [No 726/2004], hereinafter “conditional marketing authorisation”.’

12 Article 2 of Regulation No 507/2006 states:

‘This Regulation shall apply to medicinal products for human use that fall under Article 3(1) and (2) of Regulation [No 726/2004] and belong to one of the following categories: …

13 Article 4 of Regulation No 507/2006, entitled ‘Requirements’, provides in paragraph 1:

‘A conditional marketing authorisation may be granted where the Committee finds that, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, all the following requirements are met:

(a) the risk-benefit balance of the medicinal product, as defined in Article 1(28a) of Directive [2001/83], is positive; …’

14 Article 5(1) of Regulation No 507/2006 is worded as follows:

‘By way of specific obligations, the holder of a conditional marketing authorisation shall be required to complete ongoing studies, or to conduct new studies, with a view to confirming that the risk-benefit balance is positive and providing the additional data referred to in Article 4(1).

In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.’

15 Under Article 6 of Regulation No 507/2006:

‘1. After its period of validity of one year the conditional marketing authorisation may be renewed annually.

2. The application for renewal shall be submitted to the [European Medicines Agency] at least six months before the expiry of the conditional marketing authorisation, together with an interim report on the fulfilment of the specific obligations to which it is subject.

3. The Committee [for Medicinal Products for Human Use] shall assess the application for a renewal, on the basis that the risk-benefit balance is to be confirmed, taking into account the specific obligations contained in the authorisation and the timeframe for their fulfilment, and shall formulate an opinion as to whether the specific obligations or their timeframes need to be retained or modified. …

4. Once a renewal application has been submitted in accordance with paragraph 2, the conditional marketing authorisation shall remain valid until a decision is adopted by the Commission in accordance with Article 10 of Regulation [No 726/2004].’

…

Background to the dispute

28 The applicant is a pharmaceutical company established in Ireland.

29 On 16 December 2022, the applicant was transferred ownership of a conditional marketing authorisation (‘MA’) for the orphan medicinal product for human use Ocaliva – obeticholic acid (‘Ocaliva’), initially granted by Commission Implementing Decision C(2016) 8685 final of 12 December 2016 granting a conditional MA under Regulation No 726/2004 for Ocaliva. That conditional MA was renewed annually from 2016 to 2023.

30 Ocaliva, the active substance of which is obeticholic acid, is a medicinal product indicated for the treatment of patients with a liver disease, primary biliary cholangitis (‘PBC’), who do not tolerate or respond well to ursodeoxycholic acid (‘UDCA’).

31 According to Section E of Annex II to Implementing Decision C(2016) 8685 final, the holder of the conditional MA had to complete two clinical studies as a specific obligation, in accordance with Article 14(7) of Regulation No 726/2004 in the version applicable at that time. The first study, namely study 747-302, aimed to analyse the clinical benefit associated with Ocaliva treatment for PBC patients who are either unresponsive or intolerant to UDCA treatment based on clinical endpoints. The second study, namely study 747-401, had as its objective an analysis of the efficacy, safety and pharmacokinetics of that medicinal product in PBC patients with moderate to severe hepatic impairment, which was intended to address the uncertainties relating to the lack of data in a population with a more advanced stage of the disease. The final reports on those studies were due to be submitted by 2023 at the latest.

32 In December 2022, the applicant submitted an application to convert the conditional MA for Ocaliva into a standard MA, in accordance with the rules of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ 2008 L 334, p. 7).

33 In the course of that procedure, the EMA’s Committee for Medicinal Products for Human Use (‘the CHMP’) concluded that study 747-302 had failed to demonstrate the clinical benefit of Ocaliva and, therefore, it issued an opinion on 12 October 2023 recommending the refusal of the variation.

34 On the same day, the European Commission initiated a procedure for review of the conditional MA for Ocaliva, by submitting an application to the CHMP, inter alia, to assess the impact of that information on the risk-benefit balance of that medicinal product and to ‘give its opinion by June 2024 on whether the [conditional MA] for [that medicinal product] should be maintained, varied, suspended or revoked’.

35 On 21 May 2024, the applicant submitted an application for renewal of the conditional MA for Ocaliva, in accordance with Article 6 of Regulation No 507/2006 (‘the renewal procedure’).

36 In the course of the procedure for review of the conditional MA for Ocaliva, the CHMP consulted, on various points, an AHEG composed of gastroenterologists and hepatologists, including patient representatives, which convened on 12 June 2024.

37 Following the assessment conducted under the procedure for review of the conditional MA for Ocaliva, the CHMP concluded, in its opinion of 27 June 2024, that the therapeutic efficacy of the orphan medicinal product had not been established and that the risk-benefit balance was not favourable. Consequently, it was of the opinion, by consensus, that that conditional MA should be revoked. The revised and final versions of that opinion and of the assessment report of that committee, which contains a scientific discussion and a section on the risk-benefit balance of that medicinal product and the reasoned recommendation for that revocation, were adopted on 29 July 2024.

38 A few days earlier, by email of 23 July 2024, the EMA had confirmed to the applicant that the renewal procedure had been initiated following its valid application and communicated a timetable for that procedure resulting in an opinion of the CHMP on the renewal by 19 September 2024.

39 By letter of 7 August 2024, the Commission informed the applicant that, in view of the developments in the procedure for review of the conditional MA for Ocaliva, the procedure for renewal of that conditional MA had become devoid of purpose and would not be resumed.

40 On 20 and 22 August 2024, the EMA responded to the applicant’s request for access to the file.

41 On 30 August 2024, the Commission adopted the contested decision, relying on the conclusions and recommendation of the CHMP in its opinion of 29 July 2024, which was issued in the procedure for review of the conditional MA for Ocaliva.

…

Forms of order sought

44 The applicant, supported by CBP Portugal, claims that the Court should:

– annul the contested decision;

– order the Commission to pay the costs.

45 The Commission contends that the Court should:

– dismiss the action;

– order the applicant to bear its own costs and pay those incurred by the Commission;

– order CBP Portugal to pay the costs relating to its intervention.

46 The EMA contends that the Court should:

– dismiss the action;

– order the applicant to pay the costs.

Law

47 In its application, the applicant puts forward five pleas in law alleging, first, infringement of the right to an effective remedy guaranteed by Article 47 of the Charter of Fundamental Rights of the European Union (‘the Charter’) and an infringement of Article 6(4) of Regulation No 507/2006, second, infringement of the right to sound administration under Article 41 of the Charter, third, infringement of the last sentence of the first paragraph of Article 116 of Directive 2001/83, as amended, and, in essence, a manifest error of assessment, fourth, in essence, a manifest error of assessment and, fifth, a breach of the principles of proportionality and the protection of legitimate expectations, and of Article 57 of Regulation No 726/2004, as amended by Regulation 2019/5.

…

Second part of the first plea, alleging infringement of Article 6(4) of Regulation No 507/2006

…

203 According to the applicant and CBP Portugal, the risk-benefit balance assessed in a procedure for renewal of a conditional MA for a medicinal product is a highly specific one since it is the ‘conditional’ risk-benefit balance for the purposes of Article 14-a of Regulation No 726/2004, as amended by Regulation 2019/5, and of Article 4 of Regulation No 507/2006.

204 The applicant submits that it follows from the relevant provisions that the criteria to be applied and the burden of proof differ between, on the one hand, the procedure for review of the conditional MA for Ocaliva and, on the other hand, the procedure for renewal of that MA.

205 By initiating the procedure for review of the conditional MA for Ocaliva, the Commission chose not to await the outcome of the procedure for renewal of that MA, whereas, in the latter procedure, in accordance with Article 6(3) of Regulation No 507/2006, the CHMP, the EMA and the Commission also examine whether the specific obligations need to be retained or modified.

206 In addition, the applicant states that the procedure for renewal of the conditional MA for Ocaliva involved the assessment of the various analyses of study 747-302, in accordance with Article 6(3) of Regulation No 507/2006.

207 In the context of the procedure for review of the conditional MA for Ocaliva, the CHMP was not asked to assess, and did not reassess, the ‘conditional’ risk-benefit balance within the specific context and meaning of a renewal assessment. It never sought to determine whether the conditions for that conditional MA were still satisfied. Nor did it assess the need to amend the specific obligations necessary to maintain that conditional MA, but considered only the possibility of converting the conditional MA into a standard MA or of revoking it entirely.

208 The applicant, supported by CBP Portugal, submits that the requirements laid down in Article 14-a of Regulation No 726/2004, as amended by Regulation 2019/5, and in Article 4 of Regulation No 507/2006 were still met at the time of publication of the CHMP opinion and the contested decision and continue to be met.

209 The applicant submits that the initiation of the procedure for review of the conditional MA for Ocaliva cannot be justified by urgency. The procedure for renewal of that conditional MA would have resulted in a final opinion of the CHMP by 19 September 2024 at the latest. By contrast, the duration of that procedure for review was more than eight months and the opinion of that committee and the termination of the procedure were planned for June 2024.

210 The Commission, supported by the EMA, disputes the applicant’s arguments.

211 In order to determine whether the Commission infringed Article 6(4) of Regulation No 507/2006 by initiating the procedure for review of the conditional MA for Ocaliva while the procedure for renewal of that conditional MA was ongoing, it is necessary to interpret the relevant provisions, in particular, first, Article 20(1) of Regulation No 726/2004, as amended by Regulation 2019/5, and secondly, Article 6(4) of Regulation No 507/2006.

212 As a general rule and as follows from settled case-law, in interpreting a provision of EU law, it is necessary to consider not only its wording but also the context in which it occurs and the objectives pursued by the rules of which it is part, bearing in mind, however, that no interpretation may exceed the limits of clear and precise wording. The legislative history of a provision of EU law may also reveal elements that are relevant to its interpretation (see judgment of 15 May 2024, Fresenius Kabi Austria and Others v Commission, T‑416/22, EU:T:2024:316, paragraph 78 and the case-law cited).

213 As regards, first of all, the wording of Article 20 of Regulation No 726/2004, as amended by Regulation 2019/5, it should be noted that that provision provides that the Commission is to act ‘immediately’ where it considers that one of the measures provided for in Titles IX and XI of Directive 2001/83, including those provided for in Article 116 of that directive, as amended, should be applied in respect of the medicinal product concerned or where the CHMP has delivered an opinion to that effect in accordance with Article 5 of that regulation.

214 It follows that the procedure for review provided for in Article 20 of Regulation No 726/2004, as amended by Regulation 2019/5, is characterised by the urgent need to act as soon as the conditions in that article have been met.

215 Moreover, neither that provision nor any other provision of Regulation No 726/2004 lays down a minimum period for initiating a procedure for review of a conditional MA for an orphan medicinal product.

216 Similarly, there is no indication in Regulation No 726/2004, as amended by Regulation 2019/5, that Article 20 thereof does not apply in situations where a procedure for renewal of a conditional MA for an orphan medicinal product is ongoing in respect of the same medicinal product.

217 Next, Article 6(4) of Regulation No 507/2006 provides that the conditional MA ‘[is to] remain valid until a decision is adopted by the Commission in accordance with Article 10 of Regulation … No 726/2004’, once the application for renewal has been submitted, in accordance with Article 6(2) of Regulation No 507/2006.

218 It is apparent from the wording of Article 6(4) of Regulation No 507/2006 that the conditional MA for a medicinal product remains valid until the Commission has taken a decision on that application.

219 Article 6(4) of Regulation No 507/2006 makes no express reference to the procedure for review, to measures taken in accordance with the first paragraph of Article 116 of Directive 2001/83, as amended, or to other reasons as to why the conditional MA for a medicinal product could be varied or cease to be valid, such as, for example, annulment by the EU judicature or waiver of the conditional MA by the holder.

220 Consequently, the wording of Article 6(4) of Regulation No 507/2006 neither excludes nor expressly allows the Commission to initiate and complete a procedure for review of a conditional MA for a medicinal product while a procedure for renewal of that conditional MA is ongoing.

221 As regards the context of the two provisions referred to in paragraph 211 above, first, it must be stated that, according to Article 1 of Regulation No 507/2006, that regulation lays down the rules on the granting of a conditional MA, which is subject to specific obligations, and that, according to Article 2, that regulation is to apply only to medicinal products for human use which also fall under Regulation No 726/2004.

222 Accordingly, as is confirmed by recital 8 of Regulation No 507/2006, the provisions of Regulation No 726/2004 apply to conditional MAs, unless Regulation No 507/2006 provides otherwise.

223 Secondly, it is apparent from the context of Article 6(4) of Regulation No 507/2006 that that provision provides for the validity of the conditional MA in the context of the renewal procedure.

224 Accordingly, given the context of Article 6(4) of Regulation No 507/2006, that provision does not lay down any absolute rule of validity for the conditional MA of a medicinal product, which precludes the possibility of the conditional MA being revoked or varied for other reasons, such as, for example, the outcome of a re-examination procedure relating to that conditional MA.

225 It follows from the foregoing that the context of the two provisions referred to in paragraph 211 above supports an interpretation according to which, in the absence of a provision to the contrary in Regulation No 507/2006, Article 20 of Regulation No 726/2004, as amended by Regulation 2019/5, remains applicable, even in a situation such as that in the present case in which a procedure for renewal of the conditional MA is ongoing.

226 As regards the objective of the two provisions referred to in paragraph 211 above, it should first of all be recalled that, as is apparent from the preamble to Regulation No 726/2004, in particular recital 19 of that regulation, the centralised procedure for the authorisation of medicinal products provided for in that regulation is based on a scientific evaluation procedure being conducted by the EMA to address the quality, safety and efficacy of medicinal products. One of the main objectives of the authorisation regime provided for in that legislation is to ensure that patients are not administered medicinal products with a negative risk-benefit balance (judgment of 19 December 2019, Vanda Pharmaceuticals v Commission, T‑211/18, EU:T:2019:892, paragraph 42).

227 The objective of ensuring that patients are not administered medicinal products with a negative risk-benefit balance is also pursued by Regulation No 507/2006, as is apparent from recital 5 of that regulation.

228 As regards, more specifically, the objective of Article 6(4) of Regulation No 507/2006, that provision seeks to ensure that medicinal products are not removed from the market except for reasons related to public health. As is apparent from recital 9 of that regulation, it is for that reason that that provision provides that conditional MAs are to remain valid until the Commission reaches a decision based on the application for renewal, as long as it is submitted within the deadline.

229 By contrast, the objective of Article 6(4) of Regulation No 507/2006 was not to prevent a conditional MA from being revoked on public health grounds. On the contrary, the legislature considered that the application of pharmacovigilance measures, as provided for in Directive 2001/83 and Regulation No 726/2004, is particularly important for medicinal products which have been granted a conditional MA, as is apparent from recital 11 of Regulation No 507/2006.

230 It follows from the foregoing that both Article 20 of Regulation No 726/2004, as amended by Regulation 2019/5, and Article 6(4) of Regulation No 507/2006 must be interpreted as meaning that the fact that a procedure for renewal of a conditional MA for a medicinal product is ongoing does not prevent the Commission from initiating a procedure for review of that conditional MA, in the circumstances provided for in paragraph 1 of that article, and from completing it before the closure of that renewal procedure.

231 The possibility for the Commission to act effectively against a potential risk to public health associated with a medicinal product for human use would be unduly limited if it were required to await the CHMP opinion in the context of a procedure for renewal of the conditional MA for that medicinal product.

232 Nor was the Commission required to await the CHMP opinion in the course of the procedure for renewal of the conditional MA for a medicinal product in the light of the specific temporal circumstances of the present case, within which the time limit for issuing that opinion was set at 19 September 2024, that is to say, three months after the date laid down for the opinion of that committee in the context of the procedure for review and the closure of that procedure. In order to be able to pursue its objective effectively, that is to say, to protect public health, the possibility of triggering a procedure for review cannot depend on the stage of a potential renewal procedure, in a situation in which the risk-benefit balance of a medicinal product concerned is not favourable.

233 Consequently, in the present case, the Commission did not infringe Article 6(4) of Regulation No 507/2006 by triggering the procedure for review of the conditional MA for Ocaliva.

234 That conclusion is not called into question by the other arguments raised by the applicant.

235 In the first place, even assuming that there are relevant differences between the procedure for review of a conditional MA for Ocaliva and the procedure for renewal of that conditional MA which are capable of affecting the applicant’s rights, such differences would result from the fact that the two procedures may apply in overlapping situations, but for which the legislature has established different rules.

236 In the second place and in any event, the applicant has not demonstrated the existence of relevant differences between the procedure for review of a conditional MA for Ocaliva and the procedure for renewal of that conditional MA which would have had an actual impact on its rights.

237 First, the applicant’s argument that the risk-benefit balance assessment in a procedure for the renewal of a conditional MA for a medicinal product is a highly specific one since it is the ‘conditional’ risk-benefit balance for the purposes of Article 14-a of Regulation No 726/2004, as amended by Regulation 2019/5, and of Article 4 of Regulation No 507/2006 is unconvincing.

238 In that regard, it must be borne in mind that Article 4 of Regulation No 507/2006, which lays down the requirements for a conditional MA for a medicinal product, refers to the definition of the ‘risk-benefit balance’ provided for in Article 1(28a) of Directive 2001/83. Similarly, Article 2 of Regulation No 726/2004, as amended by Regulation 2019/5, refers to that definition.

239 It is apparent from the definitions of ‘risk-benefit balance’ and ‘risks related to use of the medicinal product’ in Directive 2001/83 that the establishment of a positive risk-benefit balance is based, first, on an assessment of the positive therapeutic effects and, secondly, on an assessment of the risks to patient health or public health relating to the quality, safety or efficacy of the medicinal product.

240 It follows that there is no difference between the definition of the concept of a ‘risk-benefit balance’ which applies in the context of the renewal procedure provided for in Article 6(3) of Regulation No 507/2006 and that which applies in the context of the procedure for review provided for in Article 20 of Regulation No 726/2004, as amended by Regulation 2019/5.

241 In addition, it is apparent from recitals 1 to 3 of Regulation No 507/2006 that the risk-benefit balance of a medicinal product which is the subject of a conditional MA must be positive and that the public health benefits arising from the immediate availability of the medicinal product concerned on the market must outweigh the risk inherent in the fact that additional data are still required.

242 In addition and in any event, given that the applicant had already completed the studies provided for as specific obligations, a procedure for renewal of the conditional MA for Ocaliva would have involved an assessment of the risk-benefit balance on the basis of the data obtained in the context of those specific obligations, even where there is no procedure for review of that conditional MA. Consequently, the applicant’s argument that an assessment of the risk-benefit balance in the context of that renewal procedure could have had a more positive result than an assessment in the context of that procedure for review cannot succeed.

243 Secondly, the difference which, according to the applicant, exists between, on the one hand, the assessment of the risk-benefit balance in the context of a procedure for renewal of the conditional MA for a medicinal product and, on the other, such an assessment in the context of a procedure for review of that conditional MA does not follow from any difference between the criteria to be applied in those two procedures either.

244 Article 6(3) of Regulation No 507/2006 provides as a requirement for a renewal of a conditional MA for a medicinal product that the ‘risk-benefit balance is to be confirmed’ by the CHMP, taking into account the specific obligations and the timeframe for their fulfilment. Neither that provision nor any other provision which applies to the renewal procedure refers to Article 4(1) of Regulation No 507/2006, which lays down the requirements for the first grant of a conditional MA to a medicinal product.

245 It follows that, in the context of a procedure for renewal of a conditional MA for a medicinal product, the CHMP is not required to determine whether the conditions for the grant of that conditional MA are still met.

246 Thirdly, assuming that, in the context of the procedure for review of the conditional MA for Ocaliva, it was for the Commission to demonstrate that the conditions laid down in the first paragraph of Article 116 of Directive 2001/83, as amended, were met, whereas, in the context of a procedure for renewal of that conditional MA, the burden of proof relating to the efficacy and safety of the medicinal product would have been borne by the applicant, as the applicant submits, the latter does not explain how that difference in the burden of proof and the fact that it falls on the Commission in the context of that procedure for review would have placed it at a disadvantage.

247 The questions as to who bears the burden of proof and, assuming that the burden of proof lies with the Commission, whether the Commission has demonstrated that the conditions of the first paragraph of Article 116 of Directive 2001/83, as amended, were met, will be addressed in the examination of the third plea.

248 Fourthly, the applicant’s argument concerning a reduction in its rights to specific obligations cannot be accepted.

249 In the course of the procedure for review of the conditional MA for Ocaliva, the Commission requested an opinion from the CHMP on whether that conditional MA should be ‘maintained, varied, suspended or revoked’. In the light of the results of study 747-302, the CHMP concluded, in its opinion of 29 July 2024, that ‘the totality of data available from randomised clinical trials and real-world data [did] not confirm the clinical benefit of [that medicinal product]’ and that, as a consequence, ‘the efficacy of [that medicinal product was] not established and [that,] therefore … the [risk-benefit] balance of [that medicinal product was] not favourable.’

250 In the light of that evidence, there is nothing to indicate that the CHMP was unaware of the possibility, in principle, of proposing a variation of the conditional MA for Ocaliva, including specific obligations. The applicant’s assertion to the contrary is unsubstantiated. On the contrary, it follows from the opinion of that committee of 29 July 2024 that it considered that no clinical benefit of that medicinal product had been confirmed. In those circumstances, its decision not to propose an amendment of that conditional MA is consistent.

251 The question as to whether the CHMP, and subsequently the Commission, took into account all the available evidence, including the data to which the applicant refers, namely the numerous studies favouring Ocaliva and the additional risk minimisation measures and the study programme proposed by the applicant which, according to the applicant, could have been regarded as the basis for amended specific obligations, will be addressed in the examination of the fourth and fifth pleas.

252 Fifthly, the applicant’s argument that no new or serious safety concerns were raised for Ocaliva in the recent renewal assessments or the recommendations from EMA’s Pharmacovigilance Risk Assessment Committee (‘PRAC’) is ineffective in the present part of the plea. The fact that the PRAC, in those recent renewal assessments or recommendations, did not raise the existence of a new or serious safety concern for that medicinal product, even if it were established, has no impact on the question whether the Commission infringed Article 6(4) of Regulation No 507/2006 by initiating the procedure for review of the conditional MA for that medicinal product.

253 Sixthly, the applicant has not raised, in the present part of the plea, any argument demonstrating a difference between the procedure for reviewing the conditional MA for a medicinal product and the procedure for renewal of that conditional MA as regards the application of general procedural rights, such as the right to be heard or the right to an effective remedy.

254 It must be concluded that the applicant has not demonstrated that the Commission infringed Article 6(4) of Regulation No 507/2006 by initiating and completing the procedure for review of the conditional MA for Ocaliva, while the procedure for renewal of that conditional MA was ongoing, or that it had infringed one of its rights resulting from that procedure.

255 Consequently, the second part of the first plea must be rejected.

The third plea, alleging infringement of the first paragraph of Article 116 of Directive 2001/83, as amended, and a manifest error of assessment

256 As a preliminary point, the applicant, supported by CBP Portugal, submits that, in the present case, it was for the Commission to establish that the conditions relating to the revocation of an MA, set out in Article 116 of Directive 2001/83, as amended, were met.

257 In the first place, the applicant submits that the Commission has not demonstrated that Ocaliva lacked therapeutic efficacy, within the meaning of Article 116 of Directive 2001/83, as amended, according to which the medicinal product in question does not enable therapeutic results to be obtained.

258 The applicant submits that, during the procedure leading to the adoption of the contested decision, neither the Commission nor the EMA assessed whether therapeutic results could be obtained from Ocaliva.

259 The applicant adds that although the CHMP found in its opinion that ‘no clinical benefit [had been] observed from treatment with Ocaliva’ and ‘concluded that the efficacy [of that medicinal product was] not established’, that conclusion, even if it were based on the intention-to-treat analysis (‘the ITT analysis’), is not based on any evidence, reason or finding capable of substantiating the assertion that ‘therapeutic results [could not] be obtained with [that] medicinal product’.

…

On those grounds,

THE GENERAL COURT (Fifth Chamber)

hereby:

1. Dismisses the action;

2. Orders Advanz Pharma Ltd to bear its own costs and those incurred by the European Commission, including those relating to the proceedings for interim relief;

3. Orders the European Medicines Agency (EMA) and CBP Portugal to bear their own costs.

( *1 ) Language of the case: English.

( 1 ) Only the paragraphs of the present judgment which the Court considers it appropriate to publish are reproduced here.